Related Experiment Video
Updated: Aug 5, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Nanotechnology - Driven Innovations in Anticoagulant Delivery and Antidote Development for Hemostasis Regulation
Jitendra Maity1, Sushil Kumar Singh2, Sovan Lal Pal3
1Bharat Technology, Affiliated by Maulana Abul Kalam Azad University of Technology Department of Industrial Pharmacy Uluberia India.
Cardiovascular & Hematological Disorders Drug Targets
|July 28, 2026
Summary
Nanotechnology enhances anticoagulant therapy with novel drug delivery systems and antidotes, improving patient outcomes. Challenges in cost and accessibility remain for widespread clinical translation of these advanced treatments.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Pharmacology
Background:
- Hemostasis is vital for blood flow and preventing bleeding.
- Anticoagulants prevent embolism, stroke, and venous thromboembolism (VTE).
- Conventional anticoagulants (heparins, VKAs) have limitations: parenteral administration, toxicity, and poor compliance.
Purpose of the Study:
- To review nanotechnology-driven drug delivery systems (DDS) for anticoagulants.
- To explore emerging antidote development for anticoagulant reversal.
- To synthesize evidence from preclinical and clinical studies on these innovations.
Main Methods:
- Review of current evidence on nanotechnology-based DDS and antidotes.
- Focus on nanocarriers: liposomes, ethosomes, cubosomes, hydrogels, SLnPs, SNEDDS.
- Analysis of emerging antidotes: idarucizumab, andexanet alfa, ciraparantag.
Main Results:
- Nanocarriers improve anticoagulant solubility, stability, targeting, and release.
- Oral DDS (solid dispersions, SNEDDS) offer alternatives to invasive parenteral routes.
- Approved antidotes (idarucizumab, andexanet alfa) and developing ones (ciraparantag) show promise.
Conclusions:
- Nanotechnology-based DDS overcome limitations of conventional anticoagulants, enhancing compliance and safety.
- Barriers to adoption include cost, immunogenicity, and regulatory hurdles.
- Antidotes improve safety but raise concerns about accessibility and affordability.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...